ANGEL ONE

(₹20/Trade)

Open Account

MOTILAL OSWAL

Open Account

Stock Market Institue

Trial Class

Book Now

IPOs, NCDs, OFS, Rights Issues, Buyback and Stock Brokers

Mainboard IPOs & FPOS SME IPOs & FPOS NCD Issues Rights Issues IPO Reports Stock Broker Stock Report

Q-Line Biotech IPO Details

Bookbuilding IPO | ₹214 Cr | Listed at NSE SME | Thu, May 21, 2026 - Mon, May 25, 2026

Q-Line Biotec IPO is a book build issue of ₹214.48 crores. The issue is entirely a fresh issue of 0.63 crore shares of ₹214.48 crore.

Q-Line Biotec IPO opens for subscription on May 21, 2026 and closes on May 25, 2026. The allotment for the Q-Line Biotec IPO is expected to be finalized on May 26, 2026. Q-Line Biotec IPO will list on the NSE SME with a tentative listing date fixed as May 29, 2026.

Q-Line Biotec IPO is set issue price band at ₹326 to ₹343 per share. The lot size for an application is 400 shares. The minimum amount of investment required by an individual investor (retail) is ₹2,74,400 (800 shares) (based on upper price). The minimum lot size for investment in HNI is 3 lots (1,200 shares), amounting to ₹4,11,600.

Hem Securities Ltd. is the book running lead manager and Purvśa Sharegistry (India) Pvt.Ltd. is the registrar of the issue. The Market Maker of the company is Hem Finlease Pvt.Ltd.

Refer to Q-Line Biotec IPO RHP for detailed Information.

IPO Open

Thu, May 21, 2026

IPO Close

Mon, May 25, 2026

Price Band

₹343 per share

Market Cap (Pre-IPO)

₹800.16 Cr

IPO Details

IPO Date

21 to 25 May, 2026
Listing Date

Fri, May 29, 2026T
Face Value

₹10 per share
Price Band

₹326 to ₹343
Issue Price

₹343 per share
Lot Size

400 Shares
Sale Type

Fresh capital only
Issue Type

Bookbuilding IPO
Listing At

NSE SME

Total Issue Size

62,53,200 shares (agg. up to ₹214 Cr)
Reserved for Market Maker

3,13,200 shares (agg. up to ₹11 Cr) Hem Finlease Pvt.Ltd.
Fresh Issue (Ex Market Maker)

59,40,000 shares (agg. up to ₹204 Cr)
Net Offered to Public

59,40,000 shares (agg. up to ₹204 Cr)
Share Holding Pre Issue

1,70,74,999 shares
Share Holding Post Issue

2,33,28,199 shares

IPO Timetable (Tentative)

IPO Open

Thu, May 21, 2026
Allotment

Tue, May 26, 2026
Credit of Shares

Wed, May 27, 2026

IPO Close

Mon, May 25, 2026
Refund

Wed, May 27, 2026
Listing

Fri, May 29, 2026

Issue Reservation

Q-Line Biotec IPO comprises a total issue size of 62,53,200 shares. The net offer to the public is 59,40,000 shares, after excluding 3,13,200 shares allotted on a firm basis. Of the Net offer 29,69,200 (49.99%) are allocated to QIB, 8,91,600 (15.01%) allocated to NII 20,79,200 (35.00%) allocated to RII.

Investor Category	Shares Offered	% of Net Issue	% of Total Issue
QIB Shares Offered	29,69,200	49.99%	47.48%
− Anchor Investor Shares Offered	17,81,200		28.48%
− QIB (Ex. Anchor) Shares Offered	11,88,000		19.00%
NII (HNI) Shares Offered	8,91,600	15.01%	14.26%
− bNII > ₹10L	5,94,400		9.51%
− sNII < ₹10L	2,97,200		4.75%
Retail Shares Offered	20,79,200	35.00%	33.25%
Firm Reservations
Market Maker Shares Offered	3,13,200		5.01%
Total Shares Offered	62,53,200	100.00%	100.00%

IPO Lot Size

Investors can bid for a minimum of 800 shares and in multiples of 400 shares thereof.

Application	Lots	Shares	Amount
Individual investors (Retail) (Min)	2	800	₹2,74,400
Individual investors (Retail) (Max)	2	800	₹2,74,400
S-HNI (Min)	3	1,200	₹4,11,600
S-HNI (Max)	7	2,800	₹9,60,400
B-HNI (Min)	8	3,200	₹10,97,600

IPO Subscription Details

IPO Stock Quote & Charts

IPO Anchor Investors

Q-Line Biotec IPO raises ₹61.10 crore from anchor investors. Q-Line Biotec IPO Anchor bid date is May 20, 2026.
📝 Anchor Investors Letter (PDF)

Bid Date	Wed, May 20, 2026
Shares Offered	17,81,200
Anchor Portion (₹ Cr.)	61.10
Anchor lock-in period end date for 50% shares (30 Days)	Thu, Jun 25, 2026
Anchor lock-in period end date for remaining shares (90 Days)	Mon, Aug 24, 2026

About Q-Line Biotech Ltd.

Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing a diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, and distribution/supply of diagnostic equipment for different diagnostic healthcare needs.

The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company’s key manufacturing segments include indigenous manufacturing of reagents (Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and Others [POC Devices & Rapid Tests]) and supplying/manufacturing of in-vitro diagnostics (IVD) and Pathology equipment & devices.

As of December 31, 2025, the total annual capacity was about 1.4 million kits (Haematology, Clinical Chemistry, Rapid/Elisa) and 1,200 Selectra Machines.

As of March 31, 2026, the manufacturing teams include 126 employees and 223 third-party workers collaborating with R&D, supply chain, and external partners to meet benchmarks.

Competitive Strengths:

Established manufacturing capabilities with focus on R&D, Reverse Engineering and quality control.
Diversified product portfolio with focus on IVD industry
Widespread distribution network with a presence across all four regions.
Long standing relationships with customers.
Experienced Promoter and Management team

Company Financials (Restated Consolidated)

Period Ended	31 Dec 2025	31 Mar 2025	31 Mar 2024	31 Mar 2023
Assets	561.34	455.49	339.25	251.58
Total Income	236.50	322.58	206.45	184.81
Profit After Tax	38.69	28.13	34.44	32.10
EBITDA	64.23	71.32	37.63	32.98
NET Worth	229.16	189.95	161.81	127.37
Reserves and Surplus	212.89	188.37	160.24	125.79
Total Borrowing	243.85	164.95	96.91	73.65
Amount in ₹ Crore

IPO Objects of the Issue

The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:

# Issue Objects

Est Amt (₹ Cr.)
1 To meet working capital requirements

93.50
2 Repayment of certain borrowing availed by the Company, in part or full

90.50
3 General Corporate Purposes
Total

183.50

Key Performance Indicator (KPI)

KPI	Dec 31, 2025	Mar 31, 2025
ROE	16.88%	17.66%
ROCE	13.32%	23.74%
Debt/Equity	1.06	0.87
RoNW	16.88%	23.74%
PAT Margin	16.65%	8.97%
EBITDA Margin	27.64%	22.73%
Price to Book Value	2.44	2.84

	Pre IPO	Post IPO
EPS (₹)	16.47	22.12
P/E (x)	20.82	15.51
Promoter Holding	96.77%
Market Cap	₹800.16 Cr.

The promoters of the company are Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal.

The value will be calculated using Equity Dilution = Share Holding Pre Issue – Share Holding Post Issue
The Pre IPO EPS is calculated based on Pre issue shareholding as on date of RHP and the latest FY earnings as of March 31, 2025 available in RHP.
The Post Issue EPS is calculated based on the Post issue shareholding and annualized FY earnings of December 31, 2025 available in RHP.

IPO Review

[Dilip Davda]

MRML is engaged in the business of milling, processing and supply of pulses, and other agri commodities. It had adopted automatic and semi-automatic milling units to scale up its operations. It posted growth in its top and bottom lines for the reported periods. Based on its recent financial data/earnings, the issue appears aggressively priced. It is operating in a highly competitive and fragmented segment, and that may not permit such higher margins. Merchant Banker has a poor track record. There is no harm in skipping this pricey offer.

Read detail review…

M R Maniveni IPO Recommendations

Review By	Subscribe	May Apply	Neutral	Avoid
Brokers	1	0	0	0
Members	0	0	0	0

IPO Subscription Status

The M R Maniveni IPO is subscribed 1.09 times on May 22, 2026 5:05:57 PM (Day 1). The public issue subscribed 0.89 times in the individual investors category, 1.00 times in the QIB category, and 1.66 times in the NII category. Check Day by Day Subscription Details (Live Status)

Category	Subscription (x)	Shares Offered	Shares bid for	Total Applications
QIB (Ex Anchor)	1.00	9,82,000	9,82,000	0
NII*	1.66	7,56,000	12,52,000	0
bNII (> ₹10L)	2.45	5,04,000	12,36,000
sNII (< ₹10L)	0.06	2,52,000	16,000
Individual Investor	0.89	17,32,000	15,44,000	0
Total	1.09	34,70,000	37,78,000	428

Total Applications: 428

*Market Maker portion is not included to NII/HNI.

IPO Review

[Dilip Davda]

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Read detail review…

Q-Line Biotec IPO Recommendations

Review By	Subscribe	May Apply	Neutral	Avoid
Brokers	0	0	0	0
Members	0	0	0	0

IPO Stock Quote & Charts

IPO Subscription Status

The Q-Line Biotec IPO is subscribed 29.42 times on May 25, 2026 11:55:00 AM (Day 3). The public issue subscribed 28.96 times in the individual investors category, 11.95 times in the QIB category, and 53.77 times in the NII category. Check Day by Day Subscription Details (Live Status)

Category	Subscription (x)	Shares Offered	Shares bid for	Total Applications
QIB (Ex Anchor)	11.95	11,88,000	1,41,95,200	39
NII*	53.77	8,91,600	4,79,45,200	18,401
bNII (> ₹10L)	65.58	5,94,400	3,89,78,400
sNII (< ₹10L)	30.17	2,97,200	89,66,800
Individual Investor	28.96	20,79,200	6,02,06,400	75,258
Total	29.42	41,58,800	12,23,46,800	93,698

Total Applications: 93,698

*Market Maker portion is not included to NII/HNI.

IPO Registrar

Bigshare Services Pvt.Ltd.

+91-22-6263 8200
ipo@bigshareonline.com
Visit Website

IPO Lead Manager(s)

Hem Securities Ltd. (Past IPO Performance)
Share India Capital Services Pvt.Ltd. (Past IPO Performance)

Lead Manager Reports

Lead Manager Performance Summary
Lead Manager Performance Tracker

Contact Details

Q-Line Biotech Ltd. Address

298-281,

Transport Nagar,

Kanpur Road Adjacent Transport Nagar Metro Station

Lucknow, Uttar Pradesh, 226012

+91 522-2435570
compliance@qlinebiotech.com
Visit Website

IPO FAQs

What is the Q-Line Biotec IPO?

Q-Line Biotec IPO is a SME IPO of 62,53,200 equity shares of the face value of ₹10 aggregating up to ₹214 Crores. The issue is priced at ₹343 per share. The minimum order quantity is 400.

The IPO opens on Thu, May 21, 2026, and closes on Mon, May 25, 2026.

Purva Sharegistry (India) Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on NSE SME.

How to apply in Q-Line Biotec IPO through Angel One?

Angel One customers can apply online in Q-Line Biotec IPO using UPI as a payment gateway. Angel One customers can apply in Q-Line Biotec IPO by login into Angel One Console (back office) and submitting an IPO application form.

Steps to apply in Q-Line Biotec IPO through Angel One

Visit the Angel One website and login to Console.
Go to Portfolio and click the IPOs link.
Go to the ‘Q-Line Biotec IPO’ row and click the ‘Bid’ button.
Enter your UPI ID, Quantity, and Price.
Submit IPO application form.
Visit the UPI App (net banking or BHIM) to approve the mandate.
Visit Angel One IPO Application Process Review for more detail.

When Q-Line Biotec IPO will open?

The Q-Line Biotec IPO opens on Thu, May 21, 2026 and closes on Mon, May 25, 2026.

What is the lot size of Q-Line Biotec IPO?

Q-Line Biotec IPO lot size is 400, and the minimum amount required for application is ₹2,74,400, with 2 lots being the minimum application size.

How to apply for Q-Line Biotec IPO?

You can apply in Q-Line Biotec IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don’t offer banking services. Read more detail about applying IPO online through Angel One , Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.

When is Q-Line Biotec IPO allotment?

The finalization of Basis of Allotment for Q-Line Biotec IPO will be done on Tuesday, May 26, 2026, and the allotted shares will be credited to your demat account by Wed, May 27, 2026. Check the Q-Line Biotec IPO allotment status.

When is Q-Line Biotec IPO listing date ?

The Q-Line Biotec IPO listing date is not yet announced. The tentative date of listing is Fri, May 29, 2026.